The European Union has funded the purchase of two advanced equipment sets for producing radiopharmaceuticals used in early cancer diagnostics. The acquisition was made by the state enterprise Medical Procurement of Ukraine (MPU) from Protek Solutions Ukraine for a total of ₴445 million.
“This funding was provided through the Ukraine Facility, enabling the procurement at a price 31.5% lower than initially expected,” – reports Humanitarian Media Hub, citing tender details from Interfax-Ukraine.
Each set includes a cyclotron — a particle accelerator that generates radioactive isotopes used to produce compounds that highlight cancerous cells during PET-CT scans. This technology allows doctors to detect oncological diseases at early stages, when recovery rates can reach up to 100%.
The nuclear medicine centers are planned for Kyiv, based at the National Cancer Institute, and Lviv, at the Regional Oncology Diagnostic and Treatment Center. Delivery of the equipment is expected in July 2027 due to the long production timeline for cyclotrons, which exceeds one year.
MPU notes that Ukraine currently has only five PET-CT scanners operating under the national healthcare guarantee program, and just two centers equipped with cyclotrons. In contrast, developed countries typically have one to three PET-CT units per million residents.
According to the National Cancer Registry, 80% of cancer cases in Ukraine are diagnosed at later stages (III–IV), significantly reducing chances of recovery. Oncologists emphasize that early detection — at stage I — can lead to successful treatment in 90–100% of cases. The new equipment is expected to improve access to timely and accurate diagnostics.
